Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TRACON Pharmaceuticals, Inc. (TCON : NSDQ)
 
 • Company Description   
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California.

Number of Employees: 19

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.77 Daily Weekly Monthly
20 Day Moving Average: 90,124 shares
Shares Outstanding: 20.08 (millions)
Market Capitalization: $35.54 (millions)
Beta: 1.82
52 Week High: $7.42
52 Week Low: $1.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.91% -12.31%
12 Week -23.71% -14.26%
Year To Date -36.10% -21.94%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4350 LA JOLLA VILLAGE DRIVE SUITE 800
-
San Diego,CA 92122
USA
ph: 858-550-0780
fax: 858-550-0786
ir@traconpharma.com http://www.traconpharma.com
 
 • General Corporate Information   
Officers
Charles P. Theuer - President and Chief Executive Officer
Scott B. Brown - Chief Financial Officer
William R. LaRue - Director
Martin A. Mattingly - Director
J. Rainer Twiford - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 89237H209
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 20.08
Most Recent Split Date: 11.00 (0.10:1)
Beta: 1.82
Market Capitalization: $35.54 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.24 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 12.74
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -45.45%
vs. Previous Quarter: -20.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -292.18
12/31/21 - -182.45
09/30/21 - -132.62
ROA
03/31/22 - -125.96
12/31/21 - -97.32
09/30/21 - -78.53
Current Ratio
03/31/22 - 1.16
12/31/21 - 1.82
09/30/21 - 2.45
Quick Ratio
03/31/22 - 1.16
12/31/21 - 1.82
09/30/21 - 2.45
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -9,559.54
12/31/21 - -8,285.26
09/30/21 - -7,302.31
Book Value
03/31/22 - 0.14
12/31/21 - 0.60
09/30/21 - 0.97
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©